Privo Technologies

Also Clin1 multiple cancers, combo Clin1 oral cancer, Clin0 skin cancer; PRV211 Clin1 solid tumors; PRV311 RD orthopedic pain; PRV411 RD GI diseases

Privo Technologies is developing innovative therapeutics to eliminate cancers and prevent recurrence. To enhance both existing cancer therapies as well as developing novel ones, Privo is using the power of localized drug delivery. This involves the use of their PRV platform, which uses nanoengineered platform technology to reformulate highly potent cytotoxic drugs such that high concentrations are only found at the tumor site. Privo’s lead asset, PRV111, has been shown to be effective in phase 3 clinical studies for head and neck cancer. PRV111 was created through Privo’s PRV platform and is an innovative system that uses cisplatin-loaded nanoparticles incorporated into a topical bioadhesive patch enabling localized treatment. PRV111 can be used on skin or any mucosa in invasive cancer offering much future potential.

Jobs: